AR038401A1 - Derivados de indazol substituidos como agentes terapeuticos - Google Patents

Derivados de indazol substituidos como agentes terapeuticos

Info

Publication number
AR038401A1
AR038401A1 ARP030100372A ARP030100372A AR038401A1 AR 038401 A1 AR038401 A1 AR 038401A1 AR P030100372 A ARP030100372 A AR P030100372A AR P030100372 A ARP030100372 A AR P030100372A AR 038401 A1 AR038401 A1 AR 038401A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
heteroarylalkyl
heterocycloalkyl
indazole
Prior art date
Application number
ARP030100372A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200450A external-priority patent/SE0200450D0/xx
Priority claimed from SE0203122A external-priority patent/SE0203122D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR038401A1 publication Critical patent/AR038401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de indazol substituidos como agentes terapéuticos en forma de una base libre o una sal farmacéuticamente aceptable, solvato o un solvato de la sal del mismo, un procedimiento para su preparación, formulaciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos en terapia. Reivindicación 1: Un compuesto de fórmula (1) en la cual R1 es arilo o heteroarilo cada uno de los cuales está opcionalmente substituido con una o más de los siguientes R3, -OR3, -OCOR3, -COOR3, -COR3, -CONR3R4, -NHCOR3, -NR3R4, -NHSO2R3, -SO2R3, -SO2NR3R4, -SR3, CN, halógeno o NO2, R2 es NO2, NH2, -NR5R6 o -NR6R7; R3 y R4 son cada uno independientemente H, alquilo C1-6, alquenilo C2-6(C3-8cicloalquilo)alquilo C0-6, fluoralquilo C1-6, heterocicloalquilo C0-6, heteroariloalquilo C0-6; y dicho alquilo C1-6, alquenilo C2-6, (cicloalquilo C3-8)alquiloC0-6, fluoralquilo C1-6, heterocicloalquilo C0-6, heteroariloalquilo C0-6 pueden estar substituidos con uno o más B; o R3 o R4 forman conjuntamente un anillo heterocíclico de 5, 6 o 7 miembros que contienen 1 a 4 heteroátomos independientemente seleccionados entre N, O y S, y dicho anillo puede estar opcionalmente substituido con uno o más B; B es R10, -COOR10, -COR10, -NHCOR10, -NR10R11, -CONR10R11, -OR10, -SO2NR10R11, CN, halógeno u oxo; R5 es fenilo o heteroarilo cada uno de los cuales están opcionalmente substituido con uno o más de R10, -OR10, -OCOR10, -COOR10, -CONR10R11, -NHCOR10, -NR10R11, -NHSO2R10, -SO2R10, -SO2NR10R11, -SR10, CN, halógeno, o NO2, R6 es H, alquilo C1-6, heterociclo alquilo C0-6, o hidroxi alquilo C1-6; R7 es alquilo C1-6, (cicloalquilo C3-8)alquilo C0-6, cicloalquenilo C5-8 alquilo C0-6 o R5alquilo C1-6; A es H, R8, -OR8, -OCOR8, -COOR8, -CONR8R9, -NHCOR8, -NR8R9, -NHSO2R8, -SO2R8, -SO2NR8R9, -SR8, CN, halógeno, heterocicloalquilo C0-6 o heteroarilalquilo C0-6; R8 y R9 son cada uno independientemente H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, heterocicloalquilo C0-6, heteroariloalquilo C0-6, y dichos alquilo C1-6, alquenilo C2-6, alquinilo C2-6, heterocicloalquilo C0-6 o heteroariloalquilo C0-6 pueden estar substituidos con uno o más B; o R8 y R9 forman conjuntamente un anillo heterocíclico de 5, 6 o 7 miembros que contiene 1 a 4 heteroátomos independientemente seleccionados entre N, O y S, y dicho anillo puede estar sustituido con uno o más B; R10 y R11 cada uno independientemente son H, alquilo C1-6, fluoralquilo C1-6 o hidroxialquilo C1-6; o R10 y R11 forman conjuntamente un anillo heterocíclico de 5, 6 o 7 miembros que contienen 1 a 4 heteroátomos independientemente seleccionados entre N, O y S y dicho anillo puede estar sustituido con uno o más B; con la condición que dicho compuesto no es 6-amino-3-(4-fluorfenil)-indazol, 6-amino-3-fenil-indazol, 6-nitro-3-fenil-indazol, 6-nitro-3-(4-nitrofenil)-indazol y que dichos compuestos no tienen una quinazolina en posición R5, como base libre o sal del mismo.
ARP030100372A 2002-02-13 2003-02-06 Derivados de indazol substituidos como agentes terapeuticos AR038401A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200450A SE0200450D0 (sv) 2002-02-13 2002-02-13 Therapeutic agents
SE0203122A SE0203122D0 (sv) 2002-10-22 2002-10-22 New Compounds

Publications (1)

Publication Number Publication Date
AR038401A1 true AR038401A1 (es) 2005-01-12

Family

ID=27736683

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100372A AR038401A1 (es) 2002-02-13 2003-02-06 Derivados de indazol substituidos como agentes terapeuticos

Country Status (7)

Country Link
US (1) US20050113370A1 (es)
EP (1) EP1476432A1 (es)
JP (1) JP2005519074A (es)
AR (1) AR038401A1 (es)
AU (1) AU2003206343A1 (es)
TW (1) TW200302722A (es)
WO (1) WO2003068754A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10037759A1 (de) * 2000-08-03 2002-07-04 Gruenenthal Gmbh Screeningverfahren
US20040077702A1 (en) * 2001-09-14 2004-04-22 Wen-Mei Fu Treatment of nuerodegenerative diseases
US7166293B2 (en) * 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
MXPA05001688A (es) 2002-08-12 2005-04-19 Sugen Inc 3-pirrolil-piridopirazoles y 3-pirrolil-indazoles como inhibidores de cinasa novedosos.
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
BRPI0507670A (pt) 2004-02-13 2007-07-17 Warner Lambert Co moduladores do receptor de androgênio
KR20060114022A (ko) 2004-02-27 2006-11-03 에프. 호프만-라 로슈 아게 인다졸 유도체 및 그들을 함유하는 약학 조성물
EP1737865A1 (en) 2004-02-27 2007-01-03 F.Hoffmann-La Roche Ag Fused derivatives of pyrazole
CA2558109A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
CN1679552A (zh) * 2004-03-15 2005-10-12 永信药品工业股份有限公司 优先抑制促炎细胞因子的释放
US7378532B2 (en) 2004-03-26 2008-05-27 Yung Shin Pharmaceutical Ind. Co., Ltd. Fused pyrazolyl compound
US7507860B2 (en) 2004-04-13 2009-03-24 Pfizer Inc. Androgen modulators
EP1740533A1 (en) 2004-04-22 2007-01-10 Warner-Lambert Company LLC Androgen modulators
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
CA2570047C (en) 2004-07-08 2010-09-28 Warner-Lambert Company Llc 4-cycloalkoxy benzonitriles as androgen modulators
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
WO2006130090A1 (en) * 2005-06-03 2006-12-07 Pronas Pharma Ab Use of a substance which inhibits endothelin type b and 5-hydroxytryptamine type 1b receptor upregulation in the treatment of ischemic disorders
MX2008002588A (es) 2005-08-25 2008-03-18 Hoffmann La Roche Inhibidores de p38-map-cinasa y los metodos para utilizarlos.
EP2102194A1 (en) 2006-12-08 2009-09-23 F. Hoffmann-Roche AG Substituted pyrimidines and their use as jnk modulators
EP2671885A1 (en) * 2012-06-05 2013-12-11 Ares Trading S.A. Imidazo-oxadiazole and Imidazo-thiadiazole derivatives
IL259810A (en) * 2018-06-04 2018-07-31 Yeda Res & Dev Mitogen-activated protein kinase kinase 7 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436913A (en) * 1980-09-05 1984-03-13 Siegfried Aktiengesellschaft 1H- and 2H- indazole derivatives
US5185350A (en) * 1991-09-23 1993-02-09 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1h-indoles,1h-indazoles,2h-indazoles, benzo (b)thiophenes and 1,2-benzisothiazoles
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
DE60234510D1 (de) * 2001-04-16 2010-01-07 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
EP1401831A1 (en) * 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
TW200302722A (en) 2003-08-16
US20050113370A1 (en) 2005-05-26
JP2005519074A (ja) 2005-06-30
AU2003206343A1 (en) 2003-09-04
WO2003068754A1 (en) 2003-08-21
EP1476432A1 (en) 2004-11-17

Similar Documents

Publication Publication Date Title
AR038401A1 (es) Derivados de indazol substituidos como agentes terapeuticos
AR053364A1 (es) Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis
ECSP056115A (es) ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA
AR040567A1 (es) Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6
AR036103A1 (es) Imidazotriazinas, procedimiento para su preparacion, uso de dichos compuestos para la manufactura de un medicamento para enfermedades neurodegenerativas y dicho medicamento
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR040477A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos
UY29177A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
AR077468A1 (es) Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AR054799A1 (es) Derivados de oxindol
PE20080067A1 (es) DERIVADOS DE TRIAZOLOPIRAZINA COMO MODULADORES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO DE HEPATOCITO (c-MET O HGFR)
PE20060299A1 (es) DIFENILIMIDAZOPIRIMIDINA E -IMIDAZOL AMINAS COMO INHIBIDORES DE ß-SECRETASA
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
PE20050664A1 (es) Derivados de 1h-imidazo[4,5-c]quinolina
AR078157A1 (es) Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer
UY28150A1 (es) Agentes terapeuticos
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
PE20181346A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CO5601039A2 (es) Oxazolidinonas de indolona y derivados de las mismas
AR065531A1 (es) Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas.
AR040333A1 (es) Uso de derivados de ciclotiocarbamatos en el tratamiento de condiciones relacionadas con hormonas
AR037906A1 (es) Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6

Legal Events

Date Code Title Description
FA Abandonment or withdrawal